In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...

This year's International Symposium on Liver Diseases (IISLD) 2024, held in the San Diego Convention Center, includes two key ...

Cerebras is playing in a huge market with insatiable investor demand, but its IPO prospectus is littered with red flags that ...

BOSTON -- Patients with severe, uncontrolled asthma had significantly higher odds of improvement in asthma-related sleep ...

We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD ...

Daryl Brown, who was prescribed the antidepressant Seroxat in childhood because of his Tourette’s syndrome and OCD, tells ...

Biohaven has surged driven by promising data from its troriluzole trials for spinocerebellar ataxia and ongoing OCD studies.

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

TD Cowen analyst Yaron Werber has maintained their neutral stance on GMAB stock, giving a Hold rating yesterday. Yaron Werber’s rating ...